Royal Bank Of Canada Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price

Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) had its target price raised by Royal Bank Of Canada from $296.00 to $305.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have an outperform rating on the specialty pharmaceutical company’s stock.

A number of other research firms also recently commented on JAZZ. Stifel Nicolaus set a $275.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Canaccord Genuity Group set a $300.00 price target on Jazz Pharmaceuticals in a report on Wednesday, August 26th. JPMorgan Chase & Co. upped their price target on Jazz Pharmaceuticals from $276.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, October 28th. Finally, Weiss Ratings downgraded Jazz Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $293.45.

Get Our Latest Report on JAZZ

Jazz Pharmaceuticals Stock Up 7.1%

Shares of JAZZ stock opened at $229.74 on Tuesday. Jazz Pharmaceuticals has a 1 year low of $128.80 and a 1 year high of $266.38. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The business’s fifty day moving average is $230.67 and its 200-day moving average is $216.80. The stock has a market cap of $14.91 billion, a PE ratio of 78.14, a price-to-earnings-growth ratio of 0.43 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last announced its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, beating the consensus estimate of ($4.04) by $0.16. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 16.55% and a net margin of 4.37%. The company’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the business posted $8.13 earnings per share. Equities analysts expect that Jazz Pharmaceuticals will post 10.87 earnings per share for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Renée Galá sold 2,000 shares of the firm’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $236.40, for a total transaction of $472,800.00. Following the transaction, the chief executive officer owned 141,394 shares in the company, valued at approximately $33,425,541.60. This trade represents a 1.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena Patil sold 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total value of $289,128.00. Following the completion of the transaction, the executive vice president directly owned 47,671 shares in the company, valued at $11,485,850.74. The trade was a 2.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 94,121 shares of company stock worth $23,337,922. 4.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in JAZZ. Bank of New York Mellon Corp raised its holdings in shares of Jazz Pharmaceuticals by 44.5% in the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after purchasing an additional 517,514 shares during the period. Tri Locum Partners LP acquired a new stake in Jazz Pharmaceuticals in the 1st quarter valued at about $29,995,000. Bank of America Corp DE grew its holdings in Jazz Pharmaceuticals by 10.9% during the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock worth $191,848,000 after purchasing an additional 99,656 shares during the period. Amundi grew its holdings in Jazz Pharmaceuticals by 2,445.3% during the first quarter. Amundi now owns 55,640 shares of the specialty pharmaceutical company’s stock worth $10,519,000 after purchasing an additional 53,454 shares during the period. Finally, Rokos Capital Management LLP bought a new position in Jazz Pharmaceuticals during the first quarter worth about $9,833,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

  • Positive Sentiment: Better-than-expected results and higher guidance: Third-quarter revenue was $1.24 billion, up 10.4% year over year and above the $1.21 billion consensus. The reported $3.88-per-share loss was narrower than analysts expected. Jazz raised its 2026 revenue forecast to about $4.78 billion–$4.85 billion, above the prior consensus near $4.7 billion. Jazz Pharmaceuticals third-quarter results
  • Positive Sentiment: $500 million share buyback: The repurchase authorization may support shareholder returns and signals management’s willingness to return capital. Jazz Pharmaceuticals announces share buyback
  • Positive Sentiment: Analyst target increases: JPMorgan, Morgan Stanley, RBC and Barclays raised their price targets and maintained positive ratings, adding to the favorable reaction to results and guidance. JPMorgan analyst recommendations Morgan Stanley analyst recommendations
  • Neutral Sentiment: Pipeline updates ahead: Jazz plans to present neuro-oncology research, including progress in its Phase 3 ACTION trial, at a November meeting. Any investment impact may depend on the data and subsequent development progress. Jazz neuro-oncology research at SNO 2026
  • Negative Sentiment: Loss versus prior-year earnings: The quarterly per-share loss contrasts with earnings of $8.13 a year earlier, and coverage noted an Actio-related charge. This tempers the otherwise strong revenue and outlook news. Jazz reports quarterly loss and beats revenue estimates

About Jazz Pharmaceuticals

(Get Free Report)

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.

Further Reading

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.